Assessment of the effects of intrastromal injection of adipose-derived stem cells in keratoconus patients.
adipose-derived stem cells
cellular therapy
keratoconus
stromal keratocyte
Journal
International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
03
04
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
To evaluate the efficacy and safety of intrastromal transplantation of adipose-derived stem cells (ASCs) in keratoconus patients. This study was conducted on 8 eyes of 8 patients with moderate to severe keratoconus. In the patients, ophthalmic assessments including visual acuity, refraction, slit lamp examination, fundoscopy, corneal topography, and confocal microscopy were performed. Autologous stem cells were used. The isolated stem cells were injected into the corneal stroma by using femtosecond laser. Surgical procedure was similar to intracorneal ring implantation. All patients were re-assessed 1, 3, and 6mo after surgery. The baseline mean visual acuity was 0.48±0.18 and improved to 0.66±0.17 after surgery and final acuity increased by 1.85±0.80 lines ( Intrastromal transplantation of ASCs has positive effects on vision and refractive parameters in most patients with keratoconus. After six months, visual acuity improved moderately, corneal parameters reduced slightly, and stromal keratocytes density increased. This modality is safe, and patients do not have any complications.
Identifiants
pubmed: 37332555
doi: 10.18240/ijo.2023.06.05
pii: ijo-16-06-863
pmc: PMC10250957
doi:
Types de publication
Journal Article
Langues
eng
Pagination
863-870Informations de copyright
International Journal of Ophthalmology Press.
Références
Exp Eye Res. 2007 Sep;85(3):305-11
pubmed: 17655845
Am J Ophthalmol. 2019 Jul;203:53-68
pubmed: 30772348
Int J Ophthalmol. 2021 Feb 18;14(2):179-185
pubmed: 33614444
Br J Ophthalmol. 2017 Nov;101(11):1583-1590
pubmed: 28844046
PLoS One. 2010 May 19;5(5):e10707
pubmed: 20502663
Int J Mol Sci. 2022 Jun 23;23(13):
pubmed: 35805991
Cornea. 2021 Jun 1;40(6):741-754
pubmed: 33591032
Int J Ophthalmol. 2022 Sep 18;15(9):1529-1537
pubmed: 36124200
Cornea. 2013 Feb;32(2):111-7
pubmed: 22580432
Electron Physician. 2017 Apr 25;9(4):4055-4063
pubmed: 28607635
Community Eye Health. 2017;30(100):71-73
pubmed: 29483748
Int J Ophthalmol. 2021 Mar 18;14(3):448-455
pubmed: 33747824
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):3013-3023
pubmed: 31310658
Biomed Res Int. 2013;2013:916136
pubmed: 23984420
Stem Cells. 2015 Mar;33(3):785-91
pubmed: 25400018
Exp Eye Res. 2012 Aug;101:16-26
pubmed: 22683947
PLoS One. 2013;8(2):e56831
pubmed: 23437251
Sci Transl Med. 2014 Dec 10;6(266):266ra172
pubmed: 25504883
J Cell Mol Med. 2012 May;16(5):1114-24
pubmed: 21883890
Stem Cells Transl Med. 2019 Nov;8(11):1192-1201
pubmed: 31290598
Biomed Res Int. 2015;2015:254237
pubmed: 25699261
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
Front Med (Lausanne). 2021 Feb 23;8:650724
pubmed: 33708786
Acta Biomater. 2018 Sep 1;77:191-200
pubmed: 30017923
Eye (Lond). 2014 Feb;28(2):189-95
pubmed: 24357835
Cornea. 2002 Mar;21(2):206-9
pubmed: 11862097
Biomaterials. 2012 Feb;33(5):1343-52
pubmed: 22078813
Stem Cell Res Ther. 2021 Apr 29;12(1):255
pubmed: 33926555
Stem Cells. 2013 Oct;31(10):2116-26
pubmed: 23897660
Adv Ther. 2019 Sep;36(9):2205-2222
pubmed: 31363996
Eye Vis (Lond). 2016 Jan 18;3:2
pubmed: 26783544
Ther Adv Ophthalmol. 2021 Jun 24;13:25158414211012796
pubmed: 34263132
Cells. 2022 Aug 16;11(16):
pubmed: 36010626
Int J Ophthalmol. 2019 May 18;12(5):717-724
pubmed: 31131228
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195